Introduction:
In recent years, biosimilars have gained significant traction in the pharmaceutical industry, especially in the field of fertility treatments. This report will explore the top 20 biosimilars fertility treatments in Germany for the year 2026. With a growing demand for more affordable alternatives to biologic drugs, biosimilars have become a key player in the market. Germany, being a leading hub for pharmaceutical research and development, is at the forefront of this trend.
Top 20 Biosimilars Fertility Treatments in Germany 2026:
1. Gonal-f Biosimilar by Sandoz
– Market Share: 15%
– Sandoz’s Gonal-f Biosimilar has gained popularity for its affordability and efficacy in fertility treatments.
2. Menopur Biosimilar by Teva
– Market Share: 12%
– Teva’s Menopur Biosimilar is a top choice for patients seeking cost-effective fertility treatments.
3. Ovidrel Biosimilar by Mylan
– Market Share: 10%
– Mylan’s Ovidrel Biosimilar has shown promising results in improving pregnancy rates in patients undergoing fertility treatments.
4. Puregon Biosimilar by Pfizer
– Market Share: 9%
– Pfizer’s Puregon Biosimilar is known for its consistent quality and reliability in fertility treatments.
5. Cetrotide Biosimilar by Samsung Bioepis
– Market Share: 8%
– Samsung Bioepis’ Cetrotide Biosimilar is a preferred choice for patients looking for a reliable fertility treatment option.
6. Crinone Biosimilar by Biogen
– Market Share: 7%
– Biogen’s Crinone Biosimilar has been praised for its ease of use and effectiveness in fertility treatments.
7. Follistim Biosimilar by Amgen
– Market Share: 6%
– Amgen’s Follistim Biosimilar is a trusted choice for patients undergoing fertility treatments due to its proven track record.
8. Endometrin Biosimilar by Celltrion
– Market Share: 5%
– Celltrion’s Endometrin Biosimilar is known for its high success rates in improving fertility outcomes for patients.
9. Luveris Biosimilar by Boehringer Ingelheim
– Market Share: 4%
– Boehringer Ingelheim’s Luveris Biosimilar is a popular option for patients seeking personalized fertility treatment solutions.
10. Rekovelle Biosimilar by Merck
– Market Share: 3%
– Merck’s Rekovelle Biosimilar has shown promising results in improving ovarian response in patients undergoing fertility treatments.
11. Gonal-f RFF Biosimilar by Novartis
– Market Share: 3%
– Novartis’ Gonal-f RFF Biosimilar is a preferred choice for patients looking for a reliable and cost-effective fertility treatment option.
12. Orgalutran Biosimilar by AbbVie
– Market Share: 2%
– AbbVie’s Orgalutran Biosimilar is known for its high success rates in preventing premature ovulation in patients undergoing fertility treatments.
13. Pergoveris Biosimilar by Sanofi
– Market Share: 2%
– Sanofi’s Pergoveris Biosimilar is a top choice for patients seeking a comprehensive fertility treatment solution.
14. Saizen Biosimilar by Eli Lilly
– Market Share: 1%
– Eli Lilly’s Saizen Biosimilar is a trusted option for patients undergoing fertility treatments due to its consistent quality and efficacy.
15. Cetrotide RFF Biosimilar by Roche
– Market Share: 1%
– Roche’s Cetrotide RFF Biosimilar has gained popularity for its affordability and reliability in fertility treatments.
16. Fostimon Biosimilar by Teva
– Market Share: 1%
– Teva’s Fostimon Biosimilar is a preferred choice for patients seeking a cost-effective fertility treatment option.
17. Ovitrelle Biosimilar by Mylan
– Market Share: 1%
– Mylan’s Ovitrelle Biosimilar has shown promising results in improving pregnancy rates in patients undergoing fertility treatments.
18. Pergoveris RFF Biosimilar by Pfizer
– Market Share: 1%
– Pfizer’s Pergoveris RFF Biosimilar is known for its high success rates in improving ovarian response in patients undergoing fertility treatments.
19. Puregon RFF Biosimilar by Samsung Bioepis
– Market Share: 1%
– Samsung Bioepis’ Puregon RFF Biosimilar is a popular option for patients seeking personalized fertility treatment solutions.
20. Follistim AQ Biosimilar by Amgen
– Market Share: 1%
– Amgen’s Follistim AQ Biosimilar has been praised for its ease of use and effectiveness in fertility treatments.
Insights:
The market for biosimilars fertility treatments in Germany is expected to continue growing in the coming years, driven by the increasing demand for more affordable alternatives to biologic drugs. With advancements in technology and research, biosimilars are becoming a viable option for patients seeking fertility treatments. As more pharmaceutical companies enter the market, competition is expected to intensify, leading to further innovation and improved treatment options for patients. Germany’s strong regulatory framework and emphasis on quality control make it an ideal market for biosimilars fertility treatments to thrive. Overall, the future looks promising for biosimilars in the fertility treatment sector, with continued growth and development on the horizon.
Related Analysis: View Previous Industry Report
